Fuso Pharmaceutical Industries Ltd operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Fuso Pharmaceutical Industries Ltd with three other
companies in this sector in Japan:
Nippon Chemiphar Co., Ltd.
sales of 35.69 billion Japanese Yen [US$317.99 million]
of which 97%
was Pharmaceutical Business),
Eiken Chemical Co., Ltd.
(33.27 billion Japanese Yen [US$296.47 million]
of which 54%
was Immunoserology Test Agent), and
Aska Pharmaceutical Company Limited
(48.53 billion Japanese Yen [US$432.38 million]
of which 91%
was Pharmaceutical Products Business).
During the year ended March of 2017, sales at
Fuso Pharmaceutical Industries Ltd were ¥46.78 billion (US$416.83 million).
increase of 2.3%
versus 2016, when the company's sales were ¥45.75 billion.
Despite this increase, sales are still
below the level achieved in 2015, when Fuso Pharmaceutical Industries Ltd
reported sales of ¥47.04 billion.
The sales level in 2017 was fairly close to the level five years ago: in 2012, Fuso Pharmaceutical Industries Ltd had sales
of ¥44.36 billion.
Sales of Pharmaceutical Business saw an increase
2.3% in 2017, from
¥45.58 billion to ¥46.61 billion.
Not all segments of Fuso Pharmaceutical Industries Ltd experienced an increase in sales in 2017:
sales of Real Estate Business fell 1.2% to ¥168.00 million.
(However, this segment's sales were only a very small portion of the company's overall sales).